📊 AURA Key Takeaways
Is Aura Biosciences, Inc. (AURA) a Good Investment?
Aura Biosciences is a pre-revenue biotech company with significant cash burn (-$64.3M operating cash flow) and no commercial revenue generation. While the company maintains strong liquidity with $47.6M cash and low leverage, the current burn rate at existing cash levels suggests limited runway without additional financing or achieving major clinical milestones. The absence of revenue combined with substantial operating losses and negative ROE/ROA indicates the company is in early-stage development with substantial execution risk.
Aura Biosciences remains a pre-revenue biotech with substantial operating and free cash flow losses, so the core fundamentals are still driven by cash consumption rather than commercial execution. The balance sheet is relatively clean, with strong liquidity and no meaningful debt, but profitability trends remain weak and the business still depends on pipeline progress and continued funding to sustain operations.
Why Buy Aura Biosciences, Inc. Stock? AURA Key Strengths
- Strong liquidity position with $47.6M cash and 9.04x current ratio providing near-term financial flexibility
- Zero debt burden with minimal financial leverage, reducing refinancing risk
- Reasonable equity base of $156.7M providing capital cushion for development activities
- Strong liquidity profile with a 9.04x current and quick ratio
- Debt-free capital structure reduces financial leverage risk
- Solid equity base of $156.67M provides balance sheet support
AURA Stock Risks: Aura Biosciences, Inc. Investment Risks
- No revenue generation with significant operating losses of -$85.6M indicating company is pre-commercial
- Severe cash burn of -$64.3M annually suggests limited runway of approximately 9 months at current burn rates without additional financing
- Biotech development risk: No evidence of approved products or positive clinical trial outcomes; success depends entirely on R&D execution and regulatory approval
- No reported revenue, limiting visibility into commercial traction and growth quality
- Large net loss and negative operating cash flow indicate ongoing cash burn
- Cash and equivalents of $47.55M are below annual operating cash outflow, raising funding runway concerns
Key Metrics to Watch
- Cash runway and path to profitability or next major financing event
- Clinical trial progress and regulatory milestones for lead programs
- Operating cash burn rate trends and any revenue-generating product approvals
- Quarterly operating cash burn versus cash and equivalents
- Any emergence of collaboration revenue, product revenue, or major late-stage clinical progress
Aura Biosciences, Inc. (AURA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 9.04x current ratio provides a solid financial cushion.
AURA Profit Margin, ROE & Profitability Analysis
AURA vs Healthcare Sector: How Aura Biosciences, Inc. Compares
How Aura Biosciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Aura Biosciences, Inc. Stock Overvalued? AURA Valuation Analysis 2026
Based on fundamental analysis, Aura Biosciences, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Aura Biosciences, Inc. Balance Sheet: AURA Debt, Cash & Liquidity
AURA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Aura Biosciences, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.75 indicates the company is currently unprofitable.
AURA Revenue Growth, EPS Growth & YoY Performance
Aura Biosciences, Inc. Dividends, Buybacks & Capital Allocation
AURA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Aura Biosciences, Inc. (CIK: 0001501796)
📋 Recent SEC Filings
❓ Frequently Asked Questions about AURA
What is the AI rating for AURA?
Aura Biosciences, Inc. (AURA) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 84% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are AURA's key strengths?
Claude: Strong liquidity position with $47.6M cash and 9.04x current ratio providing near-term financial flexibility. Zero debt burden with minimal financial leverage, reducing refinancing risk. ChatGPT: Strong liquidity profile with a 9.04x current and quick ratio. Debt-free capital structure reduces financial leverage risk.
What are the risks of investing in AURA?
Claude: No revenue generation with significant operating losses of -$85.6M indicating company is pre-commercial. Severe cash burn of -$64.3M annually suggests limited runway of approximately 9 months at current burn rates without additional financing. ChatGPT: No reported revenue, limiting visibility into commercial traction and growth quality. Large net loss and negative operating cash flow indicate ongoing cash burn.
What is AURA's revenue and growth?
Aura Biosciences, Inc. reported revenue of N/A.
Does AURA pay dividends?
Aura Biosciences, Inc. does not currently pay dividends.
Where can I find AURA SEC filings?
Official SEC filings for Aura Biosciences, Inc. (CIK: 0001501796) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AURA's EPS?
Aura Biosciences, Inc. has a diluted EPS of $-1.39.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is AURA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Aura Biosciences, Inc. has a SELL rating with 84% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is AURA stock overvalued or undervalued?
Valuation metrics for AURA: ROE of -51.5% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy AURA stock in 2026?
Our dual AI analysis gives Aura Biosciences, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is AURA's free cash flow?
Aura Biosciences, Inc.'s operating cash flow is $-64.3M, with capital expenditures of $271.0K.
How does AURA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -51.5% (avg: 15%), current ratio 9.04 (avg: 2).